Drugs / OKT10-B10
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04579523 | Jun 2027 → Dec 2028 expected | plasma cell myeloma | Fred Hutchinson Cancer Center | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OKT10-B10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04579523 ↗ |
| Modality | Monoclonal antibody | “²¹¹At-OKT10-B10 is a monoclonal antibody” NCT04579523 ↗ |
| Route | Intravenous | “Given IV” NCT04579523 ↗ |